CXCR2 and ovarian carcinoma: Our in vitro and in vivo results indicated that co-targeting the CXCR2 proangiogenic cytokine axis with anti-VEGF inhibition is an effective strategy to provide extended therapeutic benefits in pre-clinical models of ovarian cancer.